RecruitingPhase 1NCT05587205

Safety and Tolerability of EO2002

Phase 1, Randomized, Masked, Sham-Controlled Study to Assess the Safety and Tolerability of EO2002 in Subjects Undergoing Cataract Surgery


Sponsor

Asociación para Evitar la Ceguera en México

Enrollment

32 participants

Start Date

Aug 30, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Age ≥ 18 years.
  • Subject has uncomplicated history of cataract that has progressed to a level requiring standard cataract extraction with intraocular lens implant surgery.
  • Decreased endothelial cell count

Exclusion Criteria12

  • All ocular criteria apply to study eye unless otherwise noted.
  • Other corneal disease
  • Macular disease that in the investigator and/or sponsor's opinion would limit the ability of the subject to demonstrate improvement in BCVA.
  • Descemet membrane detachment.
  • History of uveitis or other ocular inflammatory disease.
  • History of incisional glaucoma surgery
  • Prior incisional eye surgery within 3 months prior to study treatment or penetrating or endothelial keratoplasty.
  • History of ocular neoplasm.
  • ETDRS BCVA in the fellow eye is worse than 35 letters (Snellen equivalent of 20/200).
  • Female who is pregnant, nursing, or planning to become pregnant, or who is of childbearing potential and not using a reliable means of contraception during the study.
  • Subject is currently participating in or has participated within the last 3 months in any other clinical trial of an investigational drug by ocular or systemic administration.
  • Any concomitant medical or psychological condition that could interfere with study participation or is otherwise not suitable for entry into the study in the opinion of the investigator.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALEO2002

Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery

OTHERSham injection

Sham injection


Locations(1)

Asociacion para Evitar la Ceguera en Mexico

Mexico City, Mexico City, Mexico

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05587205


Related Trials